Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Change in Acquisitions & Divestments: 2020-2025

Historic Change in Acquisitions & Divestments for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to $156.2 million.

  • Nurix Therapeutics' Change in Acquisitions & Divestments rose 40.93% to $156.2 million in Q3 2025 from the same period last year, while for Aug 2025 it was $597.2 million, marking a year-over-year increase of 58.58%. This contributed to the annual value of $459.5 million for FY2024, which is 42.25% up from last year.
  • Per Nurix Therapeutics' latest filing, its Change in Acquisitions & Divestments stood at $156.2 million for Q3 2025, which was up 9.73% from $142.3 million recorded in Q2 2025.
  • In the past 5 years, Nurix Therapeutics' Change in Acquisitions & Divestments registered a high of $159.5 million during Q4 2024, and its lowest value of $41.0 million during Q1 2023.
  • Its 3-year average for Change in Acquisitions & Divestments is $110.9 million, with a median of $105.6 million in 2023.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first skyrocketed by 1,180.08% in 2021, then slumped by 30.23% in 2023.
  • Over the past 5 years, Nurix Therapeutics' Change in Acquisitions & Divestments (Quarterly) stood at $55.0 million in 2021, then spiked by 53.54% to $84.5 million in 2022, then dropped by 9.33% to $76.6 million in 2023, then skyrocketed by 108.21% to $159.5 million in 2024, then spiked by 40.93% to $156.2 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $156.2 million for Q3 2025, versus $142.3 million for Q2 2025 and $139.2 million for Q1 2025.